{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.46","upperLimit":"15.57","value":"12.4"},{"groupId":"OG001","lowerLimit":"11.24","upperLimit":"20.37","value":"15.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"description":"OS is defined as the time from first dose of enfortumab vedotin to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"MEDIAN","populationDescription":"Full analysis set: includes all enrolled participants who received at least one dose of enfortumab vedotin.","reportingStatus":"POSTED","timeFrame":"Cohort 1: median follow-up: 61.0 months (range 59.63, 62.36); Cohort 2: median follow-up time: 45.8 months (range 44.91 to 48.95)","title":"Overall Survival (OS): Final Analysis","type":"SECONDARY","unitOfMeasure":"Months"}